Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a...
Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused o...
Zimmer Biomet beat Q4 estimates with $2.02 billion in sales and $2.31 EPS.
Stephens & Co. analyst Mason Carrico downgrades Paragon 28 (NYSE:FNA) from Overweight to Equal-Weight and lowers the pri...
Canaccord Genuity analyst Kyle Rose downgrades Paragon 28 (NYSE:FNA) from Buy to Hold.
Needham analyst Mike Matson downgrades Paragon 28 (NYSE:FNA) from Buy to Hold and maintains the price target from $13 to $13.
Zimmer Biomet agrees to acquire Paragon 28 for $1.1 billion, with a non-tradeable CVR up to $1 per share. Deal expected to clos...
William Blair analyst Brandon Vazquez downgrades Paragon 28 (NYSE:FNA) from Outperform to Market Perform.
